Abstract. Objective: To evaluate outcomes and toxicities in patients with thyroid cancer treated with intensity-modulated radiation therapy (IMRT). Methods: This was a single institution retrospective review of 10 patients with thyroid cancer treated with IMRT at Fox Chase Cancer Center between May 2001 and June 2008. The median age was 69 years. Among the 10 patients, seven had papillary carcinoma, two had T3 and 8 had T4 disease, eight had N1 disease, and two had distant metastases. Radioactive iodine was given to all patients, while the median radiotherapy (RT) dose was 60 Gy. Results: Median follow up was 28.5 months (range: 4.5-to-50.6 months). The Kaplan-Meier estimates of 3-year local control, locoregional control, and overall survival rates 90%, 90%, and 80%, respectively. Nine patients had grade 2 skin toxicity, 10 had grade 2 pharyngitis/esophagitis, 2 had grade 2 laryngitis, and 3 had grade 3 laryngitis. Few grade 2 or 3 late toxicities were observed. Conclusions: IMRT is effective in the postoperative setting for the postoperative treatment of thyroid cancer. Long-term follow-up is still needed to assess the incidence of late toxicities. Keywords • IMRT • Thyroid cancer • Radio-iodine therapy • RT toxicities Turaka, A., Li, T., Yu, J.Q., Nicolaou, N., Burtness, B., Lango, M.N., Ridge, J.A., and Feigenberg, S.J.: Intensity modulated radiation therapy (IMRT) for thyroid cancer. Thyroid Science 5(1):CLS1-5, 2010. Full Text Free in pdf format © 2010 Thyroid Science